…Teva Highly selective β₁-blocker The most β₁-selective of the routinely used beta-blockers, with documented mortality benefit in heart failure from CIBIS-II…

…the loop of Henle. The dose–response relationship is a threshold curve, not a line: below the threshold nothing happens, and in renal failure the…

…choose when reversibility matters. With a half-life of 9 minutes and the effect gone 20–30 minutes after the infusion ends, it is useful…

…and heart failure resembles that of selective COX-2 inhibitors and is seen already at doses below 100 mg/day and with short treatment duration…

…2 diabetes in EMPA-REG OUTCOME, reduced heart failure events regardless of ejection fraction in EMPEROR-Reduced and EMPEROR-Preserved, and slowed renal function decline…

…no clinically significant negative inotropic effect and can therefore be used in heart failure with reduced ejection fraction when blood pressure or angina requires it…

…symptomatic patient with HFrEF who remains above 70 beats per minute despite maximally tolerated beta-blockade, where SHIFT demonstrated reduced risk of heart failure hospitalisation.

…in severe renal failure, in the bleeding-prone patient, and when surgery or thrombolysis may become necessary at short notice. The disadvantages are continuous infusion…

…ACE inhibitor Prodrug hydrolysed to enalaprilat. Reduces mortality in heart failure with reduced ejection fraction — the effect is dose-dependent, and underdosing is more often…

…determines its use. Amoxicillin is therefore not first-line for uncomplicated acute otitis media — that role belongs to phenoxymethylpenicillin — but for treatment failure, recurrent otitis…

…Candesartan Krka Candemox Angiotensin II receptor blocker (ARB) Prodrug hydrolysed to candesartan during absorption that binds the AT₁-receptor tightly and slowly reversibly — hence the…

…extends well beyond the diabetes indication. DAPA-HF demonstrated reduced cardiovascular death and worsening heart failure with reduced ejection fraction, DELIVER showed equivalent benefit with…